Device procedure markets, November 2026
Published November 21, 2026
Growth in the hottest device procedures came from new surgeons, not busier ones; neuromodulation and embolization are leaving the hospital; and in some states fee-for-service claims now see barely a third of Medicare cases.
Growth came from new surgeons, not busier ones
SI joint fusion doubled since 2019, and so did the number of surgeons doing it, while each surgeon's volume stayed flat.
In the fastest-growing device procedures, the count of surgeons doing them rose almost as fast as the cases. Volume per surgeon barely moved, and for neurovascular embolization it fell: the growth is new adopters, each still building a practice in the procedure.
The mature categories run the other way. Coronary intervention lost about one named surgeon in six over the same years and its fee-for-service cases fell faster still; lumbar fusion lost about one in twelve, with each remaining surgeon doing as much as before. Fewer surgeons hold the volume.
| Procedure | Surgeons | Cases per surgeon |
|---|---|---|
| SI joint fusion | 81 → 169 | 63 → 62 |
| Aneurysm & intracranial embolization | 201 → 428 | 40 → 35 |
| LAA occlusion & loop recorders | 2,065 → 2,942 | 36 → 41 |
| EP ablation | 1,774 → 2,325 | 52 → 56 |
| Coronary intervention (PCI) | 6,086 → 5,056 | 50 → 43 |
| Lumbar fusion | 2,566 → 2,356 | 40 → 40 |
Neuromodulation and embolization are leaving the hospital
Six in ten spinal cord stimulator procedures billed to Medicare are now done in a surgery center, up from four in ten in 2019.
Peripheral nerve stimulation and intrathecal pumps moved the same way, from under a third in surgery centers to over half. Tumor and fibroid embolization went further: from almost none in the office to more than half, as office-based labs took it on. Kyphoplasty and vertebroplasty are drifting into the office too.
When the site moves, so does the buyer: a surgery center's owners or an office-based lab, not a hospital value committee, and sometimes the surgeons themselves own part of it.
| Procedure | Site | Share |
|---|---|---|
| Spinal cord & DRG stimulation | Surgery center | 40% → 60% |
| Peripheral nerve stimulation & intrathecal pumps | Surgery center | 31% → 54% |
| Tumor & fibroid embolization | Office | 3% → 55% |
| Kyphoplasty & vertebroplasty | Office | 21% → 30% |
In some states, claims see barely a third of Medicare
An estimated 63% of Medicare procedure volume in Rhode Island and Michigan is in Medicare Advantage, against 26% in Maryland.
CMS's public procedure counts cover traditional fee-for-service Medicare only. Nationally an estimated 52% of Medicare procedure volume is now in Medicare Advantage, but the share runs from a few percent in Alaska to nearly two thirds in parts of the Midwest and New England.
That is why lumbar fusion looks 7% smaller than in 2019 in fee-for-service claims, yet about 20% bigger once Medicare Advantage is counted (estimated). Comparing two states, or one state over time, on claims alone compares different slices of the market.
Two states hold almost a third of SI joint fusion's growth
Texas and Florida added about 3,500 Medicare SI joint fusion cases between 2019 and 2024 (estimated), 29% of the national increase, with fewer than 40 named surgeons between them.
California, Ohio, Colorado and Georgia follow, each adding several hundred. A handful of surgeons per state account for most of the named volume, so one new adopter changes a state's market noticeably.
The forecast keeps SI joint fusion among the fastest growers to 2030, with EP ablation, LAA occlusion and loop recorders, peripheral nerve stimulation and lung bronchoscopy; each state's figure carries an 80% range on its market page.
How these figures are made
CMS Medicare surgeon claims 2019 and 2024, summed over the 50 states and DC; site of care from CMS's procedure summary (PSPS) 2019 and 2025. Surgeon counts are the surgeons CMS names, those with 11 or more Medicare patients on a code. All-Medicare figures add Medicare Advantage patients at each state’s enrollment share, and the forecast carries cases per resident 65+ forward with the Census projection: both are MedaRep estimates. See How to size a procedure market, the method and each procedure’s page for the states and ranges. Release r20261120-1437.
Quoting these figures: please cite “MedaRep, Device procedure markets, November 2026” with a link to this page. Questions or corrections: spd@medarep.com.